6sense is on a mission to revolutionize the way B2B organizations create revenue by predicting customers most likely to buy and recommending the best course of action to engage anonymous buying teams. 6sense Revenue AI is the only sales and marketing platform to unlock the ability to create, manage and convert high-quality pipeline to revenue. Customers report 2X increases in average contract value, 4X increases in win rate and 20-40% reduction in time to close deals. Know everything, do anything, with 6sense.
Accacia is an AI-enabled platform to help real estate and infrastructure companies (developers, asset managers, financial institutions, operators, and governments) meet their net-zero goals. Real estate and infrastructure contribute to ~44% of global CO2 emissions and at the given speed, it’s expected to cost the world's financial sector $24.2tn, making it one of the most critical sectors to tackle the #climatechange problem. Our platform automates the measurement of scope 1, 2, and 3 carbon emissions for operating assets, and embodied carbon for under-construction assets.
Aetion is a health care analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs health care’s most critical decisions — what works best, for whom, and when — to guide product development, commercialization, and payment innovation.
We are one of the largest independent automated driving technology providers in the world. Our holistic approach to driving automation tackles three main industry challenges: software, development and validation tools, and processing hardware. Our team of over 230 works in offices in the USA, Japan, and Hungary to ensure our products are solving the real-world challenges of driving automation. We rely on our team’s expertise in artificial intelligence, sensor fusion, 3D graphics and real-world automated driving workloads, developed utilizing our global test fleet to provide robust solutions. As a result, our market-ready products can accelerate the safe and affordable deployment of ADAS and automated driving bringing these life-saving technologies to the public sooner.
Robots have the potential to reshape our existence. Our mission is to leverage robotics to improve universal quality of life. Robots will become one of the most impactful and effective tools humanity has ever created. We believe robots should do the work humans don’t want to do. We pursue ambitious goals to make this a reality. We’re not satisfied making incremental improvements to the status quo but are driven to change the paradigm altogether. Our robots are versatile, capable of solving numerous tasks with a single embodiment.
Arta Finance is the digital family office for the world. It empowers more people to gain the financial superpowers that, until now, were only accessible by ultra-high-net-worth individuals. Traditional family offices typically hire teams of professionals to access sophisticated financial strategies, exclusive investment opportunities, or connections to finance and lifestyle professionals. Through technology, Arta aims to bring these advantages to millions more people globally.
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.